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Introduction
Despite the great advances in both primary and secondary 
prevention, cardiovascular diseases still represent the 
main cause of death in Western countries (1). Metabolic 
derangements such as diabetes, obesity, and dyslipidemia 
are critical factors that directly promote the development 
of coronary artery disease, stroke, and heart failure and 
dramatically affect the prognosis of subjects affected by 
cardiovascular diseases (1). 
These metabolic abnormalities are frequently associated 
in the context of metabolic syndrome. Metabolic syndrome 
has a significant impact on the general population with 
a prevalence ranging from 25% to 35% (1,2). Metabolic 
syndrome and diabetes promote atherosclerotic plaque 
formation and rupture; they promote changes in cardiac 
geometry and functional abnormalities such as cardiac 
hypertrophy and diastolic dysfunction; they increase 
the cardiac susceptibility to ischemia and maladaptive 
remodeling; they are independently associated with the 
incidence of heart failure (1,2). At the molecular level, 
metabolic syndrome and diabetes induce oxidative stress, 
mitochondrial dysfunction, endoplasmic reticulum stress, 
and apoptosis (3). These abnormalities are responsible for 
endothelial dysfunction, cardiomyocyte hypertrophy and 
cardiac fibrosis and dysfunction associated with metabolic 
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syndrome and diabetes (3). This evidence strongly indicates 
that, aside from the battle to improve primary prevention 
critical for the reduction of metabolic syndrome and 
diabetes incidence, which unfortunately in many cases 
is lost, it is crucial to develop new therapeutic strategies 
aimed at reducing the cellular abnormalities induced by 
these morbid conditions. However, this can be possible 
only if we better elucidate the mechanisms through which 
obesity, dyslipidemia, and hyperglycemia induce cellular 
abnormalities and dysfunction. 
Accumulating lines of evidence indicate that obesity, 
diabetes, and metabolic syndrome are associated with a 
significant impairment of autophagy in multiple organs 
(4-13). Autophagy is an evolutionarily conserved cellular 
mechanism for degradation of old damaged proteins and 
organelles through their sequestration by double membrane 
vesicles called autophagosomes that subsequently deliver 
their content to lysosomes for final digestion (14). 
Autophagy is  a beneficial  mechanism for cellular 
homeostasis by guaranteeing the normal turnover of 
mitochondria and protein and by providing new substrates 
for protein synthesis and energy production (14,15). 
Autophagy is also involved in the physiological regulation 
of metabolic processes (4-11,14,15). In both genetic and 
dietary models of obesity, autophagy is inhibited in the 
liver thereby promoting ER stress and insulin resistance 
(4,6). Autophagy defects in pancreatic β-cells contribute to 
the transition from obesity to diabetes (7,16). Autophagy 
is also reduced in the mediobasal hypothalamus of obese 
animals (9). Impairment of hypothalamic autophagy was 
found to promote increased food intake, to reduce energy 
expenditure and to exacerbate the progression of obesity 
and whole-body insulin resistance (9). Autophagy is also 
impaired in macrophages during obesity, leading to an 
increased immune response and tissue inflammation (8). 
Autophagy was also found to be inhibited in the adipose 
tissue by obesity, although other works conflicted with this 
finding by demonstrating that autophagy is activated in the 
adipose tissue in the presence of metabolic abnormalities, 
where it favors adipogenesis (11). In addition, proteinuria-
induced autophagy is impaired in the kidneys of obese 
animals thereby worsening proximal tubule damage (10). 
Multiple studies in recent years have investigated 
whether obesity, diabetes, and metabolic syndrome affect 
autophagy in the heart both in unstressed and stressed 
conditions (12,13,17-32). Although it is still debated 
whether these conditions affect more the autophagosome 
formation with respect to the autophagic flux or vice versa 
(18,19), the most relevant information emerging from 
the majority of these studies is that cardiac autophagy is 
inhibited by metabolic derangements (12,13,17,18-29). 
Autophagy defects are associated with cardiac abnormalities 
and increased susceptibility to cardiac stress in the presence 
of obesity and reactivation of autophagy appears to be 
cardioprotective (12,13,19,23,28). This evidence opens up 
new scenarios where autophagy reactivation may represent 
a potential future therapeutic intervention to reduce cardiac 
abnormalities in patients with metabolic abnormalities.
All these aspects will be discussed in our review article 
together with the potential ways to reactivate autophagy in 
the context of obesity, metabolic syndrome, and diabetes.
The impact of obesity and diabetes on cardiac 
autophagy 
In recent years, numerous studies have clarified the 
role of autophagy in the heart (17,33-35). Autophagy 
is required for the maintenance of cardiac function and 
structure at baseline (17,33-35). In addition, autophagy 
is progressively inhibited during aging, and such decline 
of autophagy is paralleled by the development of aging-
induced cardiac abnormalities (17,33-35). Autophagy also 
plays a critical role in the regulation of cardiomyocyte 
survival and death during stress (17,33-35). Although 
high activation of autophagy is detrimental in specific 
cardiac stress conditions, autophagy is usually an adaptive 
mechanism regulating the cardiac response to stress. 
Autophagy is rapidly activated during myocardial ischemia 
and starvation where it reduces infarct size by limiting the 
ATP reduction and ER stress and by favoring mitochondrial 
turnover (13,36). A similar protective effect is observed 
in response to chronic myocardial infarction and pressure 
overload, where autophagy offsets cardiac remodeling and 
dysfunction in response to these stresses (37,38). Autophagy 
is also a protective mechanism in cardiac diseases caused by 
the accumulation of misfolded proteins, where autophagy 
limits ER stress (39). Overall, this evidence strongly 
indicates that autophagy is a critical protective mechanism 
during cardiac stress. Therefore, defects of this pro-survival 
mechanism would affect both cardiac homeostasis and 
response to stress. This was confirmed by a recent study 
that demonstrated that autophagy activation is inversely 
correlated with mortality in patients undergoing cardiac 
surgery (40).
Obesity, diabetes, and metabolic syndrome are morbid 
conditions associated with an increased incidence of 
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cardiovascular diseases (1-3). They favor the development 
of endothelial dysfunction and atherosclerosis, thereby 
leading to myocardial infarction and stroke. In addition, 
these conditions directly affect cardiac geometry and 
function, leading to cardiac hypertrophy and fibrosis, 
cardiac dysfunction, and heart failure (1-3,41,42). All 
these abnormalities are associated with oxidative stress, 
mitochondrial dysfunction, and ER stress (43). In addition, 
obesity and metabolic syndrome increase the susceptibility 
to myocardial ischemia, thereby suggesting a defect in the 
cardiomyocyte’s ability to respond to energy stress (44-46). 
In recent years, numerous studies investigated whether 
all these defects induced by metabolic derangements 
are associated with abnormalities of cardiac autophagy 
(12,13,17-32). These studies employed different dietary 
and genetic models of obesity, metabolic syndrome, and 
both type I and type II diabetes. Although autophagosome 
accumulation was studied through different markers in these 
studies, in most of the cases the ability of autophagosomes 
to properly fuse with lysosomes (autophagic flux) was not 
investigated and this aspect led to some differences in 
the interpretation of the results. In fact, autophagosome 
accumulation may be a consequence either of an increased 
formation or a reduced clearance, and this aspect can be 
clarified only by specifically assessing the flux (47). The 
most important and relevant information that can be 
extrapolated from all these studies is that autophagy is 
clearly inhibited in the heart in the context of obesity and 
diabetes (12,13,17-29). Metabolic abnormalities can affect 
both the formation of autophagosomes and flux depending 
upon the animal model, the duration of the disease, and 
experimental conditions. 
Cardiac autophagy is impaired in animals with diet-
induced insulin resistance, metabolic syndrome, and 
type II diabetes. We found that high-fat diet (HFD)-
induced obesity and metabolic syndrome impair cardiac 
autophagy at baseline and after myocardial ischemia, as 
indicated by a reduced number of autophagosomes with 
and without lysosomal inhibitors (GFP-LC3 puncta) (13). 
Autophagy inhibition by obesity increased the susceptibility 
to myocardial ischemia. Consistent with our results, He 
et al. showed inhibition of autophagy by HFD, and data 
from Mentzer’s group also confirmed a reduction in 
autophagosome number (mCherry-LC3 puncta) in the 
hearts of mice fed a similar type of HFD (60% of calories 
from fat), thus indicating reduced autophagosome formation 
(23,47). Recent studies also showed reduced LC3-II levels 
and increased p62 accumulation in mice with HFD-induced 
obesity, again indicating reduced autophagosome formation 
(18,21,48,49). In these studies autophagy inhibition by 
HFD was exacerbated by adiponectin deletion, whereas 
it was rescued by macrophage migration inhibitory factor 
(MIF) knockout and catalase overexpression. This data 
was also confirmed in large animals. Ossabaw pigs with 
metabolic syndrome induced by an atherogenic diet also 
displayed reduced cardiac autophagy, as indicated by 
reduced levels of LC3-II and Beclin-1, which paralleled the 
development of cardiac abnormalities and dysfunction (24). 
Similarly, hypercholesterolemia in Yucatan pigs fed high 
cholesterol diet for 4 weeks inhibited LC3-II/I ratio and 
cardiac tolerance to myocardial ischemia (25). 
Interestingly, HFD was also shown to inhibit autophagy 
by affecting the fusion of autophagosomes with lysosomes. 
In mice fed with HFD (45% of calories from fat) for 
12 weeks and fasted for 6 hours before all the analyses, 
LC3-II and p62 levels in the heart were found to be 
increased with respect to controls (22). Interestingly, LC3-II 
and p62 levels increased after lysosome inhibition in mice 
fed with control diet, whereas they did not further increase 
in HFD mice. These results indicate a defect in autophagic 
flux and confirm the study by Xu et al. demonstrating an 
impairment of autophagic flux in HFD mice, which can 
be rescued by Akt2 gene deletion (19). In addition, this 
evidence corroborates the study by Mellor et al., which for 
the first time reported an accumulation of LC3-II and p62 
in the hearts of mice with type II diabetes induced by high-
fructose diet (30). 
Of note, two recent studies from Ren’s group showed 
that under a similar regimen of HFD, cardiac LC3-II levels 
can be either decreased or increased as a consequence 
of autophagy inhibition (18,19). We speculate that these 
works may suggest that HFD affects both autophagosome 
formation and flux at the same time. Whether a reduction 
of autophagosome formation or an impairment of flux is 
the most prominent defect of cardiac autophagy induced by 
HFD may depend on the duration and type of the diet, the 
severity of obesity and associated metabolic abnormalities, 
gender and age, degree of cardiac hypertrophy and 
dysfunction, mouse strain, circadian factors, and different 
experimental conditions. Interestingly, chronic flux 
inhibition may transcriptionally inhibit LC3 (47), thereby 
suggesting a secondary inhibition of autophagosome 
formation and, in general, a tight relationship between 
autophagosome formation and clearance. 
Cardiac autophagy is also impaired in mice with 
type I diabetes. In mice with streptozotocin-induced 
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type I diabetes and in OVE26 diabetic mice, cardiac 
autophagosome production, as indicated by LC3-II levels, is 
significantly decreased with and without lysosome inhibitors 
(26-28). Autophagic flux was also found to be inhibited 
in mice with streptozotocin-induced diabetes, through 
inhibition of SIRT1 and RAB7 (29).
The main mechanism through which autophagy is 
impaired in the hearts of mice with obesity and diabetes 
is the activation of mTOR signaling, a strong negative 
regulator of autophagy (13,18,19,21,24,48,50). mTORC1 
was found to be activated by HFD and in models of 
diabetes. We found a deregulated Rheb/TORC1 activation 
in the hearts of mice fed HFD that is responsible for 
autophagy suppression (13). AKT2 activation was also found 
to be activated by HFD and to promote mTOR activation 
and autophagy inhibition (19). AMPK, a negative regulator 
of mTOR, is suppressed in the hearts of diabetic mice 
(13,18,19,21,26-29,48). Of note, inhibition of AMPK was 
also found to inhibit autophagy in these animals through 
an increased interaction between Beclin-1 and BCL-2 (28), 
thereby confirming our previous evidence demonstrating 
that MST1-dependent Beclin-1-BCL-2 interaction 
negatively regulates autophagy and cardiomyocyte 
survival (37). SIRT1, a protein deacetylase known to 
promote autophagy, was also found to be inhibited 
by diabetes (24,29). Lipids can affect autophagic flux 
through a superoxide-dependent impairment of lysosomal 
acidification (22). Interestingly, Rodriguez-Navarro’s group 
previously showed that lipotoxicity may also directly affect 
chaperone-mediated autophagy, an alternative form of 
protein degradation (51). 
Potential therapeutic efficacy of autophagy 
reactivation for the treatment of diabetes-
induced cardiovascular abnormalities 
Obesity and diabetes are associated with the development of 
cardiovascular abnormalities (1-3). Recent work consistently 
demonstrated that cardiac autophagy is inhibited in these 
two conditions (12,13,17-29). The most intriguing and 
relevant aspect of this evidence is whether reactivation 
of autophagy may prevent or reduce the cardiovascular 
abnormalities induced by metabolic derangements. Recent 
studies suggest that this may be true. Reactivation of 
autophagy in mice with type I and II diabetes improved 
cardiac function and reduced cardiac abnormalities (27-29), 
although a recent study from Liang’s group, which was 
conducted on mice with type I diabetes, conflicted with 
this notion (26). Restoration of autophagic flux by Akt2 
deletion and reactivation of autophagosome formation by 
Mif knockout also improved cardiac function in mice fed 
HFD (18,19). We found that rapamycin treatment restored 
autophagy and improved the myocardial tolerance to 
ischemia in mice with HFD-induced obesity and metabolic 
syndrome (13). The protective effects of rapamycin 
were lost in the presence of autophagy disruption. This 
evidence, coupled with recent results obtained in other 
organs where autophagy reactivation reduced diabetes-
induced abnormalities (4-6), supports the idea that boosting 
autophagy may be a therapeutic intervention in patients 
with diabetes. 
Several approaches might be suitable for activating 
cardiac autophagy in patients with metabolic abnormalities 
(Figure 1). As mentioned before, mTORC1 signaling 
is activated in the heart and vasculature of mice with 
obesity and diabetes (13,18,19,21,24,48,50,52). When it 
is hyperactivated, mTORC1 signaling is detrimental by 
inducing cardiac hypertrophy and cellular senescence and 
by reducing autophagy (53). mTORC1 inhibition was 
shown to reduce diabetic cardiomyopathy, HFD-induced 
increases in infarct size after both myocardial and cerebral 
ischemia, and endothelial cell senescence (13,50,52). This 
suggests that mTOR inhibitors might be appropriate for 
autophagy reactivation and treatment of diabetes-induced 
cardiovascular abnormalities. Rapamycin is the most studied 
mTOR inhibitor and there is a large amount of evidence 
in the literature indicating its beneficial effect against 
chronic maladaptive cardiac remodeling, hypertrophy and 
acute ischemia (53). However, rapamycin might not be an 
ideal drug for chronic treatment, particularly in patients 
with diabetes, since it can disrupt the mTORC2, which 
promotes cardiomyocyte survival, and would aggravate the 
insulin resistance status (54). A recent work from Sussman’s 
group demonstrated that selective mTORC1 inhibition by 
PRAS40 reduces diabetic cardiomyopathy and improves 
metabolic status and insulin sensitivity in mice with HFD-
induced diabetes (50). This suggests that a selective 
mTORC1 inhibition by PRAS40, or potentially by Astrin, 
an mTORC1 inhibitor (55) or by Rheb inhibition (13), 
could be an appropriate way to treat cardiac abnormalities 
induced by metabolic derangements. 
AMPK activators may also represent an alternative 
approach to reactivate autophagy in the diabetic heart. 
AMPK was found to be inhibited in the hearts of mice 
with both genetically and dietarily induced diabetes 
(13,18,19,21,26-29,48). AMPK is a positive regulator of 
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autophagy by inhibiting the mTORC1 pathway, by directly 
phosphorylating ULK1, or by modulating the Beclin-1-
BCL-2 interaction (28,56). In mice with type I diabetes, 
reactivation of AMPK by metformin rescued cardiac 
autophagy and diabetes-induced cardiac anomalies. The 
beneficial effects of metformin on cardiomyocytes exposed 
to hyperglycemia were lost in the presence of autophagy 
disruption (28). Metformin is probably the best candidate 
to activate autophagy in the context of diabetes, particularly 
of type II diabetes, since metformin can also improve 
insulin sensitivity and lower glycemia at the same time. 
Interestingly, a recent study demonstrated that catalase 
overexpression rescues HFD-induced suppression of 
autophagy by reactivating AMPK (21). These results are 
supported by our previous work showing that ROS oxidize 
and inhibit AMPK, whereas thioredoxin-1 preserves AMPK 
activation by reducing it (57). Notably, physiological 
levels of ROS are critical for autophagy activation during 
physiological processes, and catalase was previously shown 
to inhibit autophagy (58). It is possible that exaggerated 
and pathological levels of ROS in the hearts of mice with 
obesity and diabetes exert a paradoxical effect on autophagy 
by inhibiting it. 
AMPK was previously shown to regulate SIRT1 activity (55). 
SIRT1 activation is also another possible approach to rescue 
autophagy in the presence of metabolic abnormalities 
(24,29). SIRT1 was found to be inhibited in the heart by 
both type I and type II diabetes. We previously found that 
SIRT1 promotes autophagy by activating the FOXO1/
RAB7 pathway (59). Resveratrol, a SIRT1 activator, was 
previously found to reactivate autophagic flux in mice with 
type I diabetes and to reduce cardiac dysfunction, oxidative 
stress, and cardiomyocyte apoptosis (29). 
Statins may also be appropriate for reducing cholesterol 
and increasing autophagy at the same time. In fact, previous 
work demonstrated that statin treatment induces mitophagy, 
a cargo-specific form of autophagy that specifically degrades 
mitochondria (60), and reduces ischemic injury (61). In 
addition, atorvastatin was previously found to reactivate 
cardiac autophagy in a pig model of metabolic syndrome (62).
A recent study demonstrated that HFD-induced obesity 
and diabetes lead to a cellular accumulation of calcium in 
the cytosol of hepatocytes, thereby leading to an impairment 
of autophagosome-lysosome fusion (4). Interestingly, this 
defect could be rescued by the calcium-channel blocker 
verapamil, thereby suggesting that this drug may also be 
suitable for autophagy reactivation in metabolic syndrome.
Dioscin was recently found to be a strong reactivator 
of autophagy in the liver of obese mice, thereby reducing 
oxidative stress and lipotoxicity (5). Soluble epoxide 
hydrolase inhibitor was also found to promote autophagy 
and inhibit ER stress in the liver of fat-1 obese mice (63).
Treatment with carbon monoxide (CO)-releasing agents 
can also promote autophagy in the hearts of mice fed HFD 
and rescue cardiac function by improving mitochondrial 
function (32). In fact, at low doses, CO is known to 
Figure 1 The potential therapeutic efficacy of boosting autophagy in the diabetic heart. Schematic representation of the potential 
therapeutic efficacy of reactivating cardiac autophagy in the presence of metabolic abnormalities.
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promote physiological effects and improve the metabolic 
status. In support of this evidence, overexpression of heme 
oxygenase-1, which promotes CO production, has recently 
been found to activate autophagy, inhibit apoptosis and 
oxidative stress, and rescue cardiac abnormalities and 
dysfunction in streptozotocin-induced diabetes (64).  
Finally, physical exercise is an important therapeutic 
intervention to treat metabolic syndrome. A recent 
work from Levine’s group showed that exercise activates 
autophagy in the skeletal muscle of mice fed HFD by 
disrupting the Beclin-1-BCL-2 interaction. Exercise 
improved glucose tolerance in obese mice, and this 
effect was lost in mice with a defect in exercise-induced 
autophagy. This data suggests that physical exercise may be 
a valid option to improve the glucose tolerance of subjects 
with metabolic syndrome and to reactivate autophagy at the 
same time.  
Perspectives
Numerous lines of evidence indicate that autophagy 
is inhibited in the presence of obesity, diabetes, and 
metabolic syndrome. Metabolic abnormalities appear to 
affect both autophagosome formation and autophagic flux. 
Future studies are required to understand how different 
metabolic abnormalities, such as obesity, hyperglycemia, 
and dyslipidemia impact the autophagic machinery 
and through which mechanisms. This would allow the 
development of specific strategies to reactivate autophagy 
in the presence of different combinations of metabolic 
abnormalities. Currently, the most promising therapeutic 
approach to rescue the autophagy suppression by metabolic 
abnormalities in the cardiovascular system is represented by 
mTORC1 inhibition. Metformin and statins are also quite 
appropriate because they can improve the metabolic status 
and increase autophagy at the same time. Ideally, molecules 
promoting autophagy by interfering specifically with the 
autophagic machinery would be the most appropriate 
agents to reactivate autophagy in the presence of metabolic 
abnormalities, so that they could be used in combination 
with the other antidiabetic and lipid-lowering drugs. In 
this regard, Levine’s group has recently developed a small 
peptide able to activate autophagy by interacting with the 
negative regulator of autophagy, GAPR-1 (65). Finally, 
future studies are encouraged to investigate how metabolic 
abnormalities specifically affect cargo-specific forms of 
autophagy, particularly mitophagy. The impact of metabolic 
derangements on mitochondrial fusion and fission also 
needs to be clarified since mitochondrial dynamics and 
autophagy affect each other, as we recently demonstrated (66).
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